Ipsen to acquire Kartos Therapeutics for up to $1.75bn
Global biopharmaceutical company Ipsen is to acquire California-based clinical-stage biopharmaceutical company Kartos Therapeutics in a transaction valued at up to $1.75bn. The deal involves an upfront cash payment of $450m, with a further $1.3bn tied to the achievement of regulatory and commercial milestones. This transaction is expected to close in the third quarter of 2026 and highlights Ipsen’s continued focus…
Ipsen strikes up to €700m deal for Swiss biotech firm
Paris-based listed global biopharmaceutical company Ipsen SA has acquired Swiss biotechnology firm Memo Therapeutics AG in a deal that could exceed €700m. This transaction will integrate a first-in-class asset into Ipsen’s clinical pipeline as it seeks to address high unmet medical needs in transplantation, and highlights a growing trend of major European pharmaceutical companies securing specialised platform technologies to drive…